Can-Fite BioPharma (CANF) Net Margin Growth (3y) (2018 - 2023)
Powered by 
Analysis
Can-Fite BioPharma (CANF) Net Margin Growth (3y) (2018 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn | -204.00 |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn | 666.00 |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn | 3,167.00 |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn | 240.00 |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn | -1,956.00 |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn | -1,144.00 |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn | 1,366.00 |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | -94.00 |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 118,544.00 |
| Sep 30, 2023 | 875,226.00 |
| Jun 30, 2023 | -556,731.00 |
| Dec 31, 2022 | 18,556.00 |
| Sep 30, 2022 | -151,718.00 |
| Jun 30, 2022 | 277,236.00 |
| Mar 31, 2022 | -171,307.00 |
| Dec 31, 2021 | 138,639.00 |
| Sep 30, 2021 | -542,267.00 |
| Jun 30, 2021 | 105,444.00 |
| Mar 31, 2021 | -99,661.00 |
| Dec 31, 2020 | 867,369.00 |
| Sep 30, 2020 | -991,083.00 |
| Jun 30, 2020 | -75,147.00 |
| Dec 31, 2019 | 5.10 Mn |
| Sep 30, 2019 | -345,410.00 |
| Jun 30, 2019 | -412,779.00 |
| Mar 31, 2019 | -216,372.00 |
| Dec 31, 2018 | -822,340.00 |
| Sep 30, 2018 | -450,993.00 |